Statement on 2.11.21, The was SP £1.0021 Jan 2022 15:50
UNBELIEVABLE
The Company's Chief Executive Officer and its largest shareholder, Lord Paul Drayson, has approached the Sensyne Board requesting approval to speak to potential third party investors in order to pursue a potential management buyout of the Company. In order to maximise value for all of the Company's shareholders, the Board has appointed J.P. Morgan Cazenove and Peel Hunt to consider a management buyout proposal ("MBO") (should one be forthcoming) and explore other buyer interest alongside considering other strategic options that would allow Sensyne to scale more rapidly, with these including strategic investment or the continued pursuit of a secondary US listing.
The Board believes that the current market value of the Company does not reflect the fair value of the electronic patient record ("EPR") health data to which the Company has access through its strategic partnership agreements with UK NHS Trusts and US health systems. Being undervalued means that Sensyne cannot execute on opportunities that may create novel treatments for patients. The Company currently has access to a data set of 22.5 million such records and has through its agreement with OMNY Inc the potential to access a further 22 million US patient records, and access to approximately 42 million clinical trial records through its agreement with Phesi Inc.